Immuneering Corporation (IMRX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immuneering Corporation (IMRX) trades at $5.25 with AI Score 49/100 (Grade C). Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates. Market cap: $191M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026IMRX stock analysis for 2026: Analysts have set a consensus price target of $12.00 for Immuneering Corporation, suggesting 128.6% upside from the current price of $5.25. The AI MoonshotScore is 49/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
IMRX: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Immuneering Corporation (IMRX) Healthcare & Pipeline Overview
Immuneering Corporation is a biopharmaceutical company concentrating on oncology and neuroscience. Its pipeline features IMM-1-104, a dual-MEK inhibitor targeting RAS/RAF-mutated cancers, and IMM-6-415 for solid tumors. The company leverages computational biology to identify novel drug targets and accelerate drug development within the competitive biotechnology sector.
What Is the Investment Thesis for IMRX?
Immuneering Corporation presents a notable research candidate within the biotechnology sector, driven by its innovative approach to drug discovery and development. The company's lead asset, IMM-1-104, targeting RAS/RAF-mutated cancers, addresses a significant unmet need in oncology. Positive clinical trial data for IMM-1-104 could serve as a major catalyst, potentially leading to accelerated regulatory approval and commercialization. Furthermore, the development of IMM-6-415 for solid tumors and the advancement of its discovery-stage oncology and neuroscience programs offer additional avenues for growth. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. Successful execution of clinical trials and strategic partnerships will be critical for realizing the full potential of Immuneering's pipeline. The company's market capitalization of $191M reflects both the potential and the inherent risks associated with early-stage biotechnology companies.
Based on FMP financials and quantitative analysis
IMRX Key Highlights
Lead product candidate IMM-1-104 targets cancers with RAS/RAF mutations, addressing a significant unmet need.
- IMM-6-415 is being developed for the treatment of solid tumors, expanding Immuneering's oncology pipeline.
- The company has five oncology programs and two neuroscience programs in the discovery stage, providing future growth opportunities.
- Immuneering leverages its proprietary Disease Cancelling Technology to identify and develop novel drug candidates.
- The company's beta of 0.43 suggests lower volatility compared to the broader market.
Who Are IMRX's Competitors?
IMRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMRX's Key Strengths?
Proprietary Disease Cancelling Technology
- Focus on targeted therapies
- Experienced management team
- Pipeline of oncology and neuroscience programs
What Are IMRX's Weaknesses?
Early-stage development company
- Limited financial resources
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
What Could Drive IMRX Stock Higher?
Clinical trial results for IMM-1-104 in RAS/RAF-mutated cancers.
- Initiation of clinical trials for IMM-6-415 in solid tumors.
- Advancement of discovery-stage oncology and neuroscience programs.
- Potential strategic partnerships with pharmaceutical companies.
What Are the Key Risks for IMRX?
Negative return on equity (-0.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for IMM-1-104 or IMM-6-415.
- Regulatory delays or rejection of drug candidates.
- Competition from established therapies and other biotechnology companies.
- Dependence on securing additional funding to support operations.
What Are the Growth Opportunities for IMRX?
- Growth opportunity 1: Expansion of IMM-1-104 into additional cancer indications represents a significant growth opportunity. By targeting different types of cancers with RAS/RAF mutations, Immuneering can broaden the potential market for its lead product candidate. The timeline for this expansion will depend on the results of ongoing and planned clinical trials.
- Growth opportunity 2: Advancing IMM-6-415 through clinical development for the treatment of solid tumors offers another key growth avenue. Solid tumors represent a major area of unmet medical need, and successful development of IMM-6-415 could lead to significant market penetration.
- Growth opportunity 3: The development of novel therapies within Immuneering's discovery-stage oncology and neuroscience programs presents a long-term growth opportunity. By identifying and validating new drug targets, the company can expand its pipeline and create additional value. These programs target components of the MAPK or mTOR pathway in oncology and address unmet needs in neuroscience, offering diverse avenues for future growth.
- Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Immuneering's product candidates. Collaborations can provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. These partnerships can also validate Immuneering's technology and increase its visibility within the industry.
- Growth opportunity 5: Leveraging computational biology to identify and validate novel drug targets provides a competitive advantage for Immuneering. By using data-driven approaches, the company can accelerate the drug discovery process and identify promising therapeutic candidates more efficiently. This technology-driven approach can lead to the development of more effective and targeted therapies, enhancing Immuneering's competitive position.
What Are IMRX's Competitive Advantages?
- Proprietary Disease Cancelling Technology for drug discovery
- Pipeline of oncology and neuroscience product candidates
- Expertise in computational biology and targeted therapies
- Intellectual property protection for its drug candidates
What Does IMRX Do?
Immuneering Corporation, established in 2008 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapies in oncology and neuroscience. Originally a subsidiary of Teva Pharmaceutical Industries Limited, Immuneering has evolved into an independent entity focused on leveraging its proprietary Disease Cancelling Technology to identify and develop novel drug candidates. The company's lead product candidate, IMM-1-104, is a dual-MEK inhibitor designed to treat various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, particularly those driven by mutations in the RAS and/or RAF pathways. IMM-6-415, another key asset, is being developed for the treatment of solid tumors. Immuneering's pipeline also includes five oncology programs in the discovery stage, targeting components of the MAPK or mTOR pathway, and two discovery-stage neuroscience programs. The company's strategic approach combines computational biology with traditional drug development methods to accelerate the identification and validation of promising therapeutic targets. Immuneering aims to address unmet medical needs by developing targeted therapies that offer improved outcomes for patients with cancer and neurological disorders.
What Products and Services Does IMRX Offer?
- Develops oncology product candidates
- Develops neuroscience product candidates
- Focuses on therapies targeting the MAPK or mTOR pathway
- Utilizes Disease Cancelling Technology for drug discovery
- Conducts clinical trials to evaluate drug efficacy
- Aims to create targeted therapies for cancer and neurological disorders
How Does IMRX Make Money?
- Develops and patents novel drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for late-stage development and commercialization.
- Generates revenue through milestone payments and royalties on partnered products.
- Conducts early-stage research and development internally.
What Industry Does IMRX Operate In?
Immuneering Corporation operates within the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The oncology market, in particular, is experiencing significant growth, driven by an aging population and advancements in personalized medicine. Companies like Immuneering are focused on developing targeted therapies that address specific genetic mutations or pathways involved in cancer development. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms, all vying for market share. Success in this industry requires a combination of scientific expertise, clinical trial execution, and strategic partnerships. Immuneering's focus on computational biology and targeted therapies positions it to capitalize on the growing demand for personalized cancer treatments.
Who Are IMRX's Key Customers?
- Patients with cancer
- Patients with neurological disorders
- Pharmaceutical companies (potential partners/licensees)
- Healthcare providers
Company Profile
Immuneering Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Benjamin J. Zeskind. IMRX has traded publicly since 2021.
Financial Health
Immuneering Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.98 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Immuneering Corporation stands at -0.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 32.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.5%, the inverse of the P/E and a quick read on earnings relative to price.
IMRX Valuation & Market Position
With a $191M market cap, Immuneering Corporation sits in the micro-cap segment of the market. Relative to its peer group, IMRX's quantitative score of 49/100 is below the peer average of 75/100.
Earnings Track Record
Immuneering Corporation has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.5% above estimates on average.
Forward Outlook
Wall Street analysts project Immuneering Corporation revenue of about $21.3M for fiscal 2026, with EPS near $-1.12. The estimate reflects 7 contributing analysts.
IMRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative therapies in development and their potential impact on patients.
- Analysts have noted the company's strong pipeline, particularly in oncology, which could position it well in a growing market.
- Increased media coverage has raised awareness about Immuneering, drawing attention from retail investors who see promise in the company's vision.
Bear Case
- Concerns about the overall biotech sector have led to cautious sentiment, with investors wary of potential regulatory hurdles.
- Some community discussions reflect skepticism about the company's ability to deliver on its ambitious timelines, leading to doubts about execution.
- Recent earnings reports have shown slower-than-expected progress, causing some investors to question the company's growth trajectory.
- Market perception remains mixed, as some investors fear that the current valuation may not be justified given the uncertainties in drug development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMRX Latest News
No recent news available for IMRX.
IMRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMRX.
Price Targets
Consensus target: $12.00
IMRX MoonshotScore
What does this score mean?
The MoonshotScore rates IMRX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benjamin J. Zeskind
CEO
Benjamin J. Zeskind serves as the CEO of Immuneering Corporation. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Immuneering, he held leadership positions at various companies, focusing on corporate strategy, business development, and financial management. He has a strong track record of driving growth and innovation in the healthcare sector. Zeskind's expertise spans across multiple therapeutic areas, including oncology and neuroscience.
Track Record: Under Benjamin J. Zeskind's leadership, Immuneering Corporation has advanced its lead product candidates, IMM-1-104 and IMM-6-415, through preclinical and clinical development. He has overseen the expansion of the company's pipeline and the strengthening of its intellectual property portfolio. Zeskind has also been instrumental in securing strategic partnerships and raising capital to support the company's growth initiatives.
Common Questions About IMRX (Healthcare)
What does the AI Score mean for IMRX?
IMRX holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates. Their lead candidates include IMM-1-104, a dual-MEK inhibitor, …
What does Immuneering Corporation do?
Immuneering Corporation is a biopharmaceutical company focused on developing novel therapies for oncology and neuroscience. The company utilizes its proprietary Disease Cancelling Technology to identify and validate drug targets, with a focus on targeted therapies that address specific genetic mutations or pathways involved in disease development.
What do analysts say about IMRX stock?
Analyst coverage of Immuneering Corporation is limited, reflecting its early-stage development status. However, analysts generally view the company's pipeline and technology platform favorably, citing the potential for IMM-1-104 and IMM-6-415 to address significant unmet needs in oncology. Key valuation metrics include the potential market size for its lead product candidates and the probability of success for its clinical trials.
What are the main risks for IMRX?
Immuneering Corporation faces several key risks, including the potential for clinical trial failures, regulatory delays, and competition from established therapies. The success of its lead product candidates, IMM-1-104 and IMM-6-415, depends on positive clinical trial outcomes and regulatory approval. The company also faces competition from larger pharmaceutical companies with greater resources and established market positions.
What is Immuneering Corporation's drug pipeline status?
Immuneering Corporation's drug pipeline includes IMM-1-104, a dual-MEK inhibitor in clinical development for RAS/RAF-mutated cancers, and IMM-6-415, in preclinical development for solid tumors. Additionally, the company has five oncology programs and two neuroscience programs in the discovery stage.
What are the key growth opportunities for IMRX in healthcare?
Immuneering Corporation's key growth opportunities lie in the expansion of IMM-1-104 into additional cancer indications, the advancement of IMM-6-415 through clinical development, and the development of novel therapies within its discovery-stage programs. The company can also expand its reach through strategic partnerships with larger pharmaceutical companies.
What are the key factors to evaluate for IMRX?
Immuneering Corporation (IMRX) holds an AI score of 49/100 (low). Analysts target $12.00 (+129%). Immuneering Corporation presents a notable research candidate within the biotechnology sector, driven by its innovative approach to drug discovery and development. Not financial advice.
How frequently does IMRX data refresh on this page?
IMRX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMRX's recent stock price performance?
Immuneering Corporation (IMRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Disease Cancelling Technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.